Lupin’s Quietly Busy Quarter: What Happened After the Big Earnings Beat

First, the scorecard

Lupin closed out FY26 (the year ended March 2026) with genuinely standout numbers. Full-year revenue came in at ₹27,488 crore, up almost 24% over FY25, while EBITDA jumped 55% to ₹8,160 crore — a margin of 29.7%, nearly 600 basis points higher than the year before. Profit after tax rose 62% to ₹5,355 crore. For the fourth quarter alone, sales grew 33% YoY to ₹7,392 crore and EBITDA nearly doubled, up 68%. By Vinita Gupta’s own description on the call, this was the company’s 15th consecutive quarter of year-on-year growth, with record sales and profitability for the year as a whole.

The growth wasn’t lopsided either. The US business — long Lupin’s swing factor — had a blowout year, up roughly 40-46% to cross the $1.3 billion mark, driven by products like Tolvaptan (where Lupin was the sole generic for a stretch) and Mirabegron. But India’s prescription business also grew a healthy 10.6% (ahead of the broader market), Other Developed Markets (Europe, Canada, Australia) grew 13%, and Emerging Markets — Brazil in particular — grew an eye-catching 35%, helped by a genuine turnaround story in Brazil where local-currency growth hit 113% in the final quarter.

Then, the promises

Earnings calls aren’t just a report card, though — they’re also a list of things management says they’re about to do. And this call had plenty:

• VISUfarma, the European ophthalmology acquisition, would close and start contributing from Q1 FY27, expanding Lupin’s specialty footprint into Italy and Spain.
• A wave of US complex-generic approvals was coming — Vinita Gupta specifically flagged Ravicti (glycerol phenylbutyrate), Saxenda, and two first-to-file products (Sacubitril Valsartan and Rivaroxaban) as material for FY27, alongside Pegfilgrastim ramping up through a new partnership with Valorum.
• On the respiratory pipeline, she said Lupin had “eight to nine product filings in FY27,” with Respimat and Etanercept filings expected within the current fiscal year.
• On biosimilars, the near-term focus was Pegfilgrastim and Ranibizumab, with European Commission approval for Ranibizumab specifically called out as a milestone target.
• Management also flagged margin headwinds for FY27 — guiding to high-single-digit revenue growth but EBITDA margins easing to around 25%, mainly because competition was expected to hit Tolvaptan and Mirabegron, Lupin’s two biggest US growth drivers this year.

That’s a lot of specific, checkable claims. So here’s a quick, plain-English tour of what Lupin actually delivered between early April and late June 2026 — and how neatly (or not) it lines up with what management told investors they were going to do.

The European speciality bet lands

Three weeks before results even came out, Lupin closed its acquisition of VISUfarma, a European eye-care specialist with more than 60 products across dry eye, glaucoma, blepharitis and retinal health — and a sales team already in place across Italy, the UK, Spain, Germany and France. On the earnings call, CEO Vinita Gupta had talked about wanting deals that come with “established commercial infrastructure” rather than just a product license. VISUfarma is exactly that: a ready-made specialty business bolted onto Lupin’s European footprint, not a science project that needs years of building.

The US generics pipeline, converting one ANDA at a time

This is where the quarter really got busy. Lupin had told investors it expected a wave of approvals in injectables, respiratory and complex generics — and over eight weeks, that wave arrived almost on schedule:

• Glycerol phenylbutyrate (generic Ravicti, a ~$337M US market) — approved in early May, the exact product Vinita Gupta had called out as “material for us in FY27.”
• Famotidine injection — a smaller hospital product, approved mid-May.
• Revefenacin inhalation solution (generic Yupelri, ~$261M market) — tentative approval, feeding the respiratory pipeline management said would carry “eight to nine filings” this year.
• Sodium sulfate/magnesium sulfate/potassium chloride tablets (generic Sutab, ~$133M market) — and this one’s a genuine prize: Lupin is the exclusive first-to-file, meaning 180 days of limited competition once it launches.
• Two oncology approvals in June — eribulin mesylate injection (with partner Natco) and enzalutamide tablets, the latter coming with two extra dosage strengths the original brand doesn’t even offer.

None of these are individually huge, but stacked together they tell a consistent story: the “more than 60 products in injectables and respiratory” pipeline Lupin described on the call isn’t theoretical — it’s actually clearing the FDA, month after month.

A new flag planted in China

Perhaps the most interesting move wasn’t even mentioned on the earnings call: Lupin received approval for oseltamivir oral suspension (a paediatric flu treatment) in China — its first-ever product approval in the country, done through a partnership with local player Yabao. It’s a small product, but a genuinely new market for Lupin, and a signal that the company’s “100+ countries” ambition isn’t standing still.

Building out the emerging-markets story, a different way

On the call, Nilesh Gupta talked up India, Brazil and South Africa as the engines of Lupin’s diabetes-and-metabolic push (think Dapagliflozin, Semaglutide). South Africa delivered news too — just not on that front. Lupin’s local subsidiary, Pharma Dynamics, partnered with Medicines360 to launch Avibela, South Africa’s first generic hormonal IUD. It’s a women’s-health move rather than a metabolic one, but it shows the South African business expanding on more than one front at once.

Early signs of life in oncology innovation

Lupin doesn’t talk much in public about its in-house drug discovery work, but it surfaced briefly in late May: Phase 1a data on LNP8701, an orally administered cancer drug candidate, was presented at the ASCO 2026 conference. The early read — well tolerated, some patients with stable disease for over a year on the drug — isn’t a blockbuster headline, but it’s tangible proof that the “innovation pipeline” management referenced on the call is more than a slide in a presentation.

And the one thing that didn’t go to plan

Not everything was on schedule. A minor corporate housekeeping item — Lupin’s Dutch subsidiary Nanomi buying a minority stake in its own Philippines unit, Multicare — got pushed from end-May to July. It’s about as low-stakes as delays get (a stake purchase in a company Lupin already controls), but worth noting if only because it’s the only thing in the quarter that didn’t land exactly when promised.

The bottom line

Strip away the press-release language and what you get is a company doing the unglamorous, repetitive work of actually executing a strategy it already announced: integrate the European acquisition, keep clearing FDA approvals one by one, push into a genuinely new market (China), and let the early-stage science quietly accumulate data points. The FY27 margin guidance was always going to be the harder test — that’s a story for the next earnings call — but on pure execution against what was promised, this was a quarter of mostly checked boxes.

_{Disclaimer: Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, membership of a SEBI recognized supervisory body (if any) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.}

_{The content in these posts/articles is for informational and educational purposes only and should not be construed as professional financial advice and nor to be construed as an offer to buy /sell or the solicitation of an offer to buy/sell any security or financial products.Users must make their own investment decisions based on their specific investment objective and financial position and using such independent advisors as they believe necessary.}

_{Windmill Capital Team: Windmill Capital Private Limited is a SEBI registered research analyst (Regn. No. INH200007645) based in Bengaluru at No 51 Le Parc Richmonde, Richmond Road, Shanthala Nagar, Bangalore, Karnataka – 560025 creating Thematic & Quantamental curated stock/ETF portfolios. Data analysis is the heart and soul behind our portfolio construction & with 50+ offerings, we have something for everyone. CIN of the company is U74999KA2020PTC132398. For more information and disclosures, visit our disclosures page here.}